Antimicrobial therapy against carbapenemase-producing bacteria: why MIC alone is not enough.
文献摘要
Carbapenemase-producing Gram-negative bacteria represent a major therapeutic challenge in infectious diseases and critical care medicine. Although antimicrobial susceptibility testing remains fundamental, reliance on minimum inhibitory concentration alone is insufficient to predict clinical success. The efficacy of antimicrobial therapy is influenced by multiple factors, including the specific carbapenemase present, bacterial species-specific resistance mechanisms, infection site pharmacology, and pharmacokinetic/pharmacodynamic target attainment. Carbapenemases belonging to Ambler classes A, B, and D confer distinct susceptibility profiles that determine the activity of novel β-lactam/β-lactamase inhibitor combinations. Furthermore, co-resistance mechanisms such as porin mutations, efflux pump overexpression, and AmpC hyperproduction frequently modify antibiotic activity. These mechanisms are particularly relevant in pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae . In critically ill patients, altered pharmacokinetics and impaired tissue penetration further complicate therapy. This review proposes a framework for antimicrobial selection against carbapenemase-producing organisms based on four key determinants: resistance mechanism, bacterial species, infection focus, and pharmacodynamic optimization.